Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
ERA-NET ON ADVANCED MANUFACTURING TECHNOLOGIES (MANUNET III)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Technologies for Factories of the Future
Action type: ERA-NET Cofund
Partnership: MANUNET III (ERA-NET)
Countries involved: Germany,Italy,Spain,Spain,Spain,Spain,Spain,Spain,Ireland,Italy,Italy,Italy,Italy,Israel,Spain,Russian Federation,Norway,Belgium,Türkiye,Romania,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Luxembourg
Call: ERA-NET on manufacturing technologies supporting industry and particularly SMEs in the global competition (H2020-NMBP-ERA-NET-2016, 2016)
Start date: 2016-10-01
End date: 2022-03-31
Duration (months): 66.0
Total project cost (EUR): 18949886.13
EU funding (EUR): 6253462.43
Participants: 28
Project status: SIGNED

Europe is facing major economic challenges that require an ambitious economic policy for the 21st century. The EU has set out its vision for Europe's social market economy in the Europe 2020 strategy, which aims at confronting our structural weaknesses through progress in three mutually reinforcing priorities : • smart growth, based on knowledge and innovation, • sustainable growth, promoting a more resource efficient, greener and competitive economy, • inclusive growth, fostering a high employment economy delivering economic, social and territorial cohesion. MANUNET III, as a continuation of MANUNET II, is aligned with the European priorities and pretends to create a smart sustainable growth in the European manufacturing sector by coordinating the research and innovation efforts in the field of advanced manufacturing with a special focus in the key areas of new production processes, adaptive manufacturing systems and technologies for the factory of the future. The project will also reinforce the territorial cohesion through an extended collaboration network. The consortium pretends to respond to the actual economic crisis by promoting the transnational research, innovation and entrepreneurship in the industrial sector, especially in the SMEs, which are the backbone of Europe's economy. Through this strategic and integrated approach to innovation in advanced manufacturing, MANUNET III pretends to maximise European, national and regional research and innovation potential.

Keywords: manunet,advanced manufacturing,smes,competitiviness
Behavioral demand-driven dynamic reorganisation of cortical networks revealed by simultaneous wide-field optical imaging and optogenetic stimulation mapping in task-performing mice (BRONC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-11-01
End date: 2020-10-31
Duration (months): 24.0
Total project cost (EUR): 187419.6
EU funding (EUR): 187419.6
Participants: 1
Project status: CLOSED

CAREER PLAN: The Experienced Researcher (ER) has revealed causal neural mechanism of cognitive memory by optogenetics and psychophysics in macaque monkeys. ER wish to combine cognitive neuroscience in monkeys and circuit-based neuroscience in mice to build a new field to study cognitive functions at the level of genetically-defined circuits. Thus, ER plans to develop and acquire new technologies in a top laboratory investigating the mouse brain. INTRODUCTION: We humans can quickly change what we do. This would require dynamic reorganization of brain networks. Recent studies have revealed differential roles of cortical layers and interneurons in local neuronal circuits. However, a mechanism that reorganise cortical networks to integrate local circuit processing has been poorly understood, while this is a core principle of the brain to work. OBJECTIVE: Elucidating mechanisms of global integration of local processing from a view point of spatiotemporally-selective causal actions of different cortical layers and interneurons. APPROACH: Spatiotemporal actions of cortical layers and interneurons in task-performing mice will be observed by wide-field optical imaging with genetically-encoded calcium or voltage indicators. Simultaneously, optogenetic stimulation mapping to layers and interneurons will visualize their causal contribution to global processing and task execution. IMPACTS: 1. Mechanisms of dynamic cortical reorganisation for switching behavior have a clinical impact for common psychiatric disorders such as obsessive-compulsive disorder in which patients can not stop repeating a single action. 2. ER transfers knowledge in monkey cognitive science to the host lab to sophisticate mouse paradigm. 3.Techniques developed by ER will be transferred to marmoset, a small non-human primate suited for gene-modification and optical observation. This program is highly beneficial for the society and the career of ER toward understanding of human mental functions.

Keywords: cortex,optical imaging,optogenetics,task performing mouse,behavioural demand
Fine tune of cellular behavior: multifunctional materials for medical implants (Bio-TUNE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Italy,Argentina,Indonesia,Germany,Spain,Malaysia,France,United Kingdom,United Kingdom,Peru
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2019, 2019)
Start date: 2020-01-01
End date: 2024-12-31
Duration (months): 60.0
Total project cost (EUR): 814200.0
EU funding (EUR): 814200.0
Participants: 10
Project status: SIGNED

Bio-TUNE aims to develop innovative multifunctional materials to produce a new generation of medical implants with cell instructive and antibacterial potential. In biomaterials science, it is well accepted that implant biointegration with surrounding tissues is a major goal. However, implant surfaces that facilitate cell adhesion, may also favor colonization of bacterial cells. Infection of biomaterials and subsequent biofilm formation can be catastrophic and significantly reduce patient quality of life, representing an emerging concern in healthcare. On the other hand, research efforts devoted to inhibit bacterial colonization are frequently related to cytotoxic agents or treatments that do not positively affect host tissues. Hence, ideally, to enhance the long-term success of medical implants, biomaterial surfaces should reduce bacterial colonization levels without compromising the physiological functions of eukaryotic cells. Yet, the majority of current approaches tend to only focus on either improving cell adhesion or preventing bacterial infection but rarely explore a combined effect. In Bio-TUNE we focus on multifunctional coatings to simultaneously address and mitigate both these problems. Thus, Bio-TUNE introduces a new mindset and different paradigms in the development of biomaterials to respond to unmet clinical needs. Bio-TUNE ambitions to 1) Study and understand the interaction of eukaryotic cells with bacteria at the biophysical and biomolecular level; 2) To develop cell instructive and antibacterial surfaces via biochemical and topographical approaches; 3) Transfer this technology to medical implants. We seek to decipher the mechanistic of eukaryotic and bacterial cell competition, generate new selective and multi-potential coatings and topographically-active patterns, and their technological transfer leading to a generation of advanced biomimetic materials for tissue regeneration and personalized medicine.

Keywords: biosensing,cell instructive materials,antibacterial surfaces,micro and nanostructured materials,surface functionalization,multifunctional coatings,immune response,medical implants
Restoring complete sensory ability for natural walking of amputees (GoSafe)

Framework: Horizon 2020 — Industrial Leadership
Action type: Innovation actions
Countries involved: Germany,Italy,Iceland,Switzerland
Call: Fast Track to Innovation (FTI) (H2020-EIC-FTI-2018-2020, 2019)
Start date: 2019-11-01
End date: 2024-04-30
Duration (months): 54.0
Total project cost (EUR): 3974137.5
EU funding (EUR): 2943671.25
Participants: 4
Project status: SIGNED

Lower limb amputees use prostheses that do not restore sensory feedback during walking. The lack of feedback increases the risk of falls of amputee, who lose confidence in the prosthesis, overusing the healthy leg, have increased fatigue, and reduced mobility. Finally, they do not feel the device as part of the body and experience phantom limb pain (pain from the missing limb). Because of these reasons, users abandon the prosthesis, with consequent low reinsertion into the working society. SensArs has developed the solution to these problems: a neuroprosthesis that allows amputees to feel sensory feedback from the prosthesis as from a real leg. So far, 3 amputees have tested its technology. The main goal of GoSafe is to improve the device and finalize a pilot trial proving safety and efficacy. The pilot trial will give insights on potential technology or clinical protocol modifications to go through a pivotal study to get CE mark for the neuroprosthesis. To reach this goal, SensArs will optimize the neuroprosthesis and integrate it with the commercial prosthetic leg of Össur, then will go through preclinical validation and clinical pilot study at UCSC and CHAR with leg amputees. With the clinical pilot study, SensArs will apply for a pivotal study for CE mark (class III device), which will allow commercialization after the project. To guarantee the product market uptake, the consortium will run during the project a study to define the strategy to get reimbursement right after the CE marking. There are no commercial devices similar to the one proposed in GoSafe. The prosthesis restoring sensory feedback will enable users to feel the prosthesis itself as part of the body, to avoid falls, and so to increase confidence in the device, which will reduce counterbalancing movements, and fatigue. The GoSafe neuroprosthesis would be a novel therapy for phantom pain and would enable the National Health Systems to save up to €330’000 per amputee, connected to a sedentary lifestyle following prosthesis abandonment. The sensory feedback system will represent a new product in the prosthetics market (valued €1.4 billion in 2016), allowing its further expansion.

Keywords: amputees,prosthetics,human machine interfaces,sensory feedback,nerve stimulation
A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells (NeoCellBank)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-05-01
End date: 2019-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%), incurring disability and large economic burden. Current pharmacological treatments for OA involve palliative therapies (NSAIDs) that work on the symptoms, becoming lengthy and expensive with multiple side effects. In this context, regenerative medicine based on stem cells appears as a good alternative, as they reverse the pro-inflammatory status of the joint and promote endogenous tissue regeneration. However, current solutions for OA mainly rely on autologous adult stem cells, obtained through invasive procedures and which hold biological properties altered by donor age and underlying inflammation. Allogeneic adult cells could be used in any individual, but a limited amplification potential limits the number of recipients. In response, we aim to revolutionize the field of regenerative medicine by introducing a unique cell therapy based on neonatal stem cells. These cells have many advantages over adult cells: source material is accessible & abundant, cells show stronger anti-inflammatory properties, and lower immunogenicity profile which allows for unrestricted allogeneic use. The main goal of our project is to finalise industrialization and bring to market our reliable cell-based solution for OA. In Phase 1 we will define the technical and commercial steps to overcome before reaching mature stage. Upon completion of this project, we foresee our product to disrupt the veterinary market of inflammatory diseases. Moreover, since the pathology mechanism for OA is shared between animals and humans, our product could work as an accelerator for human applications. Importantly, the effort will pay off for Vetbiobank, estimating to earn €26 million profits, hire 19 people and reach a Return of Investment of 4.2 Euros after 5 years in the market.

Keywords: osteoarthritis,regenerative therapy,allogeneic therapy,stem cells,chronic inflammatory diseases,cell therapy,bio waste valorization
Tools to access and analyze un-reduced mass spectrometry data to accelerate access to biotherapeutics (A2MStools)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Coordination and support actions
Countries involved: Switzerland
Call: FET Innovation Launchpad (H2020-FETOPEN-2018-2019-2020-4, 2020)
Start date: 2021-04-01
End date: 2022-03-31
Duration (months): 12.0
Total project cost (EUR): 142857.14
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

Biotherapeutics, such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), constitute an increasingly important class of molecular drugs. Accelerating our society’s access to novel biotherapeutics-based therapies and diagnostic tests for existing and new clinical indications, including those caused by COVID-19, is critical. The exceptional specificity and selectivity of mass spectrometry (MS) renders this analytical technique a powerful tool in development of biotherapeutics-based drugs and clinical diagnostics. Nevertheless, even Orbitrap Fourier transform mass spectrometry (FTMS), which dominates the high-performance MS field, may demonstrate limited performance in structural analysis of the very complex mAbs and ADCs. Indeed, while the user-accessible Orbitrap data (processed mass spectra with reduced information) may be of a sufficient quality and information content for small molecule and isolated proteins analysis, it is not for the complex biotherapeutics. We identified the limiting factor that inhibits biotherapeutics structure analysis being the absence of hardware and software tools to acquire (access and provide to the end-users) and analyze the un-reduced data (e.g., time-domain signals or transients). With these tools in hands, the end-users would be able to increase performance and productivity of their biopharma workflows on the Orbitraps (e.g., leading to increased sensitivity and resolution, and thus leading to faster identification of more species and their deeper sequencing), as well as create novel workflows, not possible otherwise. The A2MStools (access & analysis MS tools) aims to address this limitation by: (i) providing access to the currently unavailable un-reduced data (transients) for the Orbitraps FTMS platforms with enabled BioPharma capabilities, and (ii) empowering analytical scientists with the data analysis tools capable of handling the datasets of unprocessed data in the most comprehensive and innovative ways.
A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline (CAREMiBRAIN)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Spain
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-03-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present innovation project with the overall objectives of marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) based on the detection of β-amyloid biomarker in the brain using two 18F-labelled tracers recently approved by FDA and EMEA for their clinical use and a validation of the clinical performance of this new diagnostic device. This new brain-dedicated PET system, targeted to Mental Disorder Units and Nuclear Medicine Units of hospitals in Europe, USA and Japan; is unique in the market and offers several advantages compared to the whole-body PET systems such as higher resolution, three times higher sensibility, a competitive price (up to three times lower), needs smaller hospital facilities, lower radiotracer dose to the patient that leads to a lesser cost to the healthcare system. Due to this improved characteristics, the new brain-dedicated PET system will help to allow an early detection of Alzheimer’s disease and other causes of cognitive decline and to use this business opportunity to ensure profitability and growth of ONCOVISION. During Phase 1, a technical/economic feasibility study is envisaged to verify the viability of the product and its clinical validation. In Phase 2, the validation of clinical performance of the product will be carried out, to enable commercialisation in Phase 3.

Keywords: positron emission tomography,alzheimer s disease,brain,molecular imaging,biomarker,radiotracer,amyloid,diagnosis
Scentsitive nature: Green leaf volatile perception in plants and insects (VOLARE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Biotechnology and Biosystems Engineering
Panel description: Biotechnology using all organisms, biotechnology for environment and food applications, applied plant and animal sciences, bioengineering and synthetic biology, biomass and biofuels, biohazards
Countries involved: Netherlands
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-02-01
End date: 2024-01-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

Plant leaves can emit large amounts of volatiles into the air. When attacked by insects, the composition of these blends changes markedly. It is well known that these changes affect not only the behavior of insects interacting with the plant but also the metabolism of the plant itself as well as its nearby competitors. However, how plants perceive these volatiles and generate a functional response is not known. My research activities have been dedicated to a group of plant volatiles emitted the earliest upon herbivory, the so-called green leaf volatiles (GLVs). I discovered a class of enzymes, present in plants and insects, that profoundly affect ecological interactions by converting the highly abundant GLV Z-3-hexenal into E-2-hexenal (Science 2010, eLife 2013, Frontiers in Plant Science 2017). These two compounds, as well as their derivatives, among which Z-3- and E-2-hexenyl acetate, have distinct effects on the behavior of herbivorous and predacious insects as well as on the metabolism of plants. Here I propose to take my program to the next level by elucidating how plants and insects perceive E-2-hexenal and hexenyl acetates. First I will use a classical mutagenesis screen and a cutting-edge technique called chemical yeast 3-hybrid (Y3H) to identify plant proteins involved in signal processing and especially perception of volatiles. With the newly identified genes in hand I will create non-responsive mutant plants to investigate the role of these key volatiles in the plant's self-recognition and its interactions with herbivorous insects and pathogens. Simultaneously, I will use Y3H to also identify insect proteins that directly interact with either E-2-hexenal or E-2-hexenyl acetate and I will create non-responsive insects using CRISPR-Cas9 and assess how this affects their behavior. This interdisciplinary research project will uncover the perception mechanism of key plant volatile signals and the roles these play in the (eco)physiology of plants and insects.

Keywords: green leaf volatiles,perception,plant insect interaction,e 2 hexenal,hexenal isomerase
Large-scale platform for motion detection and fluorescence imaging in zebrafish models of neurological disorders (PhenoTECH)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: Romania
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2020-10-01
End date: 2022-09-30
Duration (months): 24.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

The PhenoTECH project aims to develop a novel technology with high-throughput capacity for screening and phenotyping of genetic models of disease. PhenoTECH will enable an unprecedented capability to monitor and control multiple parameters that will significantly contribute to advancing fundamental and biopharmaceutical research, strongly accelerating discovery of novel treatments for debilitating neurodegenerative diseases. PhenoTECH’s immediate impact will be on the ERC Consolidator Grant, ALS-Networks, where we intend to utilize the power of zebrafish for high-throughput functional screens to uncover defective cellular pathways and to identify therapeutic targets for ALS and related neurodegenerative disorders. High-throughput phenotype-based screening efforts have until now been hampered by the lack of technology that would allow for parallel monitoring of behavioral, cellular and physiological markers of disease. To overcome this limitation, PhenoTECH will build an innovative platform for automated phenotypic analysis consisting of three modules: i) custom designed multiwell plates with the capacity for in-well perfusion of solutions, greatly facilitating and optimizing drug delivery, wash-out, temperature and oxygenation control; ii) state of the art motion (motor) tracking with analysis of spontaneous and evoked locomotion of zebrafish larvae; iii) fluorescence detection of genetically-encoded transgenic line reporters to enable live monitoring and imaging of cellular processes and neuronal activity. By combining these three capabilities, PhenoTECH will surpass any existing commercial product on the market and will enable low-cost, large-scale screening capability for development of efficient treatments to neurodegenerative diseases. PhenoTECH will have a strong societal and economic impact by providing a technological leap forward that will boost fundamental and biopharmaceutical research & development.

Keywords: zebrafish,neurological disorders,amyotrophic lateral sclerosis,epilepsy,motor neurons,locomotion,fluorescent imaging,high throughput screening,detection assays,therapeutic targets,pharmacological screening,genetic models